Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478948 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL5487104 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL31474558 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL5483240 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL303904 | 0.97 | — | — | |
| SCHEMBL29034631 | 0.93 | ALDH1A1 (0.56) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL8815707 | 0.93 | TSHR (0.56) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| Ether SCHEMBL7854223 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRTHRBHSD17B10LMNA | |
| SCHEMBL15899339 | 0.89 | ALDH1A1 (0.50) | ALDH1A1TSHRTHRBEPHX2 | |
| SCHEMBL31341392 | 0.87 | ALDH1A1 (0.48) | ALDH1A1TSHRTHRBHSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123195-A1 | TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121259-A1 | TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |
| US-20210220328-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL SA (ES) | 2021-07-22 | — | — | US | disclosed |
| WO-2020245291-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL, S.A. (ES) | 2020-12-10 | — | — | WO | disclosed |
| CN-111886230-A | Pyrrole derivatives as ACC inhibitors | 阿尔米雷尔有限公司 | 2020-11-03 | — | — | CN | disclosed |
| EP-3724182-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | Almirall S.A. (ES) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019115405-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL, S.A. (ES) | 2019-06-20 | — | — | WO | disclosed |
| US-9231274-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-01-05 | — | — | US | disclosed |
| US-9136560-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20130196225-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130095379-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | KOTATO MINORU (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20120244426-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-1744394-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-3947183-A | LIQUID CRYSTAL DISPLAY SYSTEM | XEROX CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | ALDH1A1 2071/4885TSHR 1237/4885THRB 3407/4885 |
| US-20210220328-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ACACA, ACACB, PCCA | ALDH1A1 129/4885TSHR 4181/4885THRB 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.